Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

7JWE

Gedatolisib bound to the PI3Kg catalytic subunit p110 gamma

Summary for 7JWE
Entry DOI10.2210/pdb7jwe/pdb
Related5JHA
DescriptorPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform, Gedatolisib (3 entities in total)
Functional Keywordspik3cg, mtor, phosphoinositide, pip3, pi3k, p110, signaling protein, transferase
Biological sourceHomo sapiens (Human)
Total number of polymer chains1
Total formula weight111342.83
Authors
Burke, J.E.,Rathinaswamy, M.K.,Harris, N.J. (deposition date: 2020-08-25, release date: 2021-03-17, Last modification date: 2023-10-18)
Primary citationRathinaswamy, M.K.,Gaieb, Z.,Fleming, K.D.,Borsari, C.,Harris, N.J.,Moeller, B.J.,Wymann, M.P.,Amaro, R.E.,Burke, J.E.
Disease related mutations in PI3K gamma disrupt regulatory C-terminal dynamics and reveal a path to selective inhibitors.
Elife, 10:-, 2021
Cited by
PubMed Abstract: Class I Phosphoinositide 3-kinases (PI3Ks) are master regulators of cellular functions, with the class IB PI3K catalytic subunit (p110γ) playing key roles in immune signalling. p110γ is a key factor in inflammatory diseases and has been identified as a therapeutic target for cancers due to its immunomodulatory role. Using a combined biochemical/biophysical approach, we have revealed insight into regulation of kinase activity, specifically defining how immunodeficiency and oncogenic mutations of R1021 in the C-terminus can inactivate or activate enzyme activity. Screening of inhibitors using HDX-MS revealed that activation loop-binding inhibitors induce allosteric conformational changes that mimic those in the R1021C mutant. Structural analysis of advanced PI3K inhibitors in clinical development revealed novel binding pockets that can be exploited for further therapeutic development. Overall, this work provides unique insights into regulatory mechanisms that control PI3Kγ kinase activity and shows a framework for the design of PI3K isoform and mutant selective inhibitors.
PubMed: 33661099
DOI: 10.7554/eLife.64691
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.55 Å)
Structure validation

226707

數據於2024-10-30公開中

PDB statisticsPDBj update infoContact PDBjnumon